Seeking Alpha HealthcareOriginal article
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch
Positive
AI Analysis
Summary
Atea Pharmaceuticals outlined peak annual U.S. net revenue potential exceeding $700M for its HCV treatment with a planned mid-2028 commercial launch.
Financial Highlights
Revenue
over $700M peak annual U.S. net revenue potential
Importance:5/10
Sentiment:
0.60
HCVrevenue guidancecommercial launch
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on August 13, 2026 1:27 AM